Month: July 2024

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Results also highlight that, in contrast to mutant-selective RAS inhibition, broad-spectrum, reversible RAS-GTP inhibition with a RAS(ON) multi-selective inhibitor alone drove durable anti-tumor activity in these models with infrequent resistance occurrence and the potential for emergence of rare persister, slow cycling cells REDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication...

Press release        Ecully, July 11, 2024 – 6.30 p.m.Spineway organizes hands-on training on total disc replacement with its ESP prostheses at IRCAD in Strasbourg The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, organized a hands-on training workshop entitled “Hands-on Total Disc Replacement featuring ESP technology” at the Institut de Recherche contre les Cancers de l’Appareil Digestif (IRCAD) in Strasbourg on June 28, 2024. During the event, Spineway’s ESP prostheses (cervical and lumbar) were presented to 25 surgeons and professionals, with a presentation of the products, their indications and two surgical approach sessions. The training workshops took place at IRCAD in Strasbourg, renowned for the quality of its facilities and were led by renowned surgeons, Dr. Biren Desai (Germany),...

WARREN, N.J., July 11, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, today released a letter to stockholders highlighting recent achievements, growth plans, and consideration of a potential share buyback. Letter to Stockholders We are pleased to share our progress and next steps that underscore our commitment to advancing science to benefit patients and physicians while supporting our stockholder’s investment. Our lead product candidate TVGN 489, an investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy, is progressing for the treatment of acute COVID-19 in vulnerable cancer patients....

Series RIKV 24 0918 RIKV 25 0115ISIN IS0000036200 IS0000036572Maturity Date 09/18/2024 01/15/2025Auction Date 07/15/2024 07/15/2024Settlement Date 07/17/2024 07/17/2024On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bills in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bills must be received by the Central Bank before 14:00 on the Settlement Date and the Bills will be delivered in electronic form on the same day. Further reference is made to the General Terms of Icelandic Treasury bills and General Terms of Auction for Treasury bills on the Government Debt Management website. For additional information please contact Magnús Freyr Hrafnsson, Government Debt Management, at +354 569 9679.

Oxurion provides clarification on the agenda of the extraordinary general shareholders’ meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, announced today it has provided clarification on the agenda of the extraordinary general shareholders’ meeting to be held on 24 July 2024 (the EGM) as set out in the convening notice published on 5 July 2024 in accordance with applicable laws. The EGM shall deliberate and vote on a potential share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share and resulting authorization to the board of directors of the Company to further implement the share consolidation during a three-year period following the date of the EGM. The...

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 3 957 404,44 €Siège social : 1, Cours Antoine Guichard42000 Saint-Etienne554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de voteet d’actions composant le capital socialau 30 juin 2024 (article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)Nombre d’actions composant le capital Nombre total de droits de vote Nombre total de droits de vote exerçables en assemblée générale400 939 713 401 401 335 401 376 507* * **  Fait le 11 juillet 2024 à 17h30AttachmentCasino_Nbre droits de vote et d’actions au 30-06-2024_Communiqué

First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases with nonsense mutations, today provided significant pipeline and financing updates. “Dosing of the first healthy...

Regulated Information July 11, 2024HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT Under the liquidity agreement entered into between Renault SA and BNP Paribas, the following resources appeared on the liquidity account on June 30, 2024:46,508 shares,€ 24,319,589.In the first half of 2024, were carried out:9,453 purchase transactions for 1,697,018 shares and € 75,155,899.12,826 sale transactions for 1,722,138 shares and € 76,170,297.For information: 1. In the previous half-year report, on December 31, 2023, the following resources appeared on the liquidity account:71,628 shares,€ 23,305,1842. In the second half of 2023, were carried out:12,269 purchase transactions for 2,498,726 shares and € 91,801,58614,467 sale transactions for 2,456,687 shares and € 90,344,1323. as of the date of the signature of the...

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today a new contract with Punch Pubs, a leading pub company in the UK. This partnership will see the deployment of Quadient’s Parcel Pending open locker network across 1,261 pub locations managed by Punch Pubs, enhancing the accessibility and convenience of parcel deliveries and returns for communities nationwide. This collaboration supports sustainable growth strategies, leveraging Punch Pubs’ nationwide commercial properties to deliver value to local populations. Quadient’s approach to selecting optimal locations is based on detailed partner carrier data, to pinpoint areas with delivery bottlenecks and high population density. Within Punch Pubs’ network mapping, Quadient has already identified 400 premium...

   Paris, 11 July 2024 – 5:45 pm Pursuant to the liquidity agreement that Rubis has entered into with Exane BNP Paribas, the liquidity account presented the following balances as at the settlement date of 30 June 2024:81,253 Rubis shares €325,422The following trades were made in the first half of 2024:346,002 securities were purchased for a total of €10,218,263 (2,262 transactions) 329,474 securities were sold for a total of €9 730 520 (1,951 transactions)Reminder:The previous half-year statement as of 31 December 2023 disclosed the following balances on the liquidity account:62,531 Rubis shares €844,745The following trades were made in the second half of 2023:111,684 securities were purchased for a total of €2,439,566 (663 transactions) 141 589 securities were sold for a total of €3,097,235 (1,056 transactions)The...